Related Experiment Video
Updated: Apr 14, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
The current and future state of companion diagnostics
Amit Agarwal1, Dan Ressler2, Glenn Snyder1
1Deloitte Consulting LLP, San Francisco, CA, USA.
Companion diagnostics are crucial for personalized medicine, with their use rapidly expanding across diseases. Despite challenges in stakeholder alignment, economic incentives and market growth indicate a bright future for this field.
Area of Science:
- Biotechnology
- Medical Diagnostics
- Personalized Medicine
Background:
- Companion diagnostics (CDx) have evolved significantly since their inception in the 1980s.
- Initial skepticism from drug developers has been overcome by the success of CDx-paired drugs like Herceptin® and Gleevec®.
- The field has expanded from oncology to multiple therapeutic areas, with a 12-fold increase in CDx-drug combinations.
Purpose of the Study:
- To analyze the growth and future trends of companion diagnostics.
- To identify challenges and opportunities within the companion diagnostics market.
- To explore the evolving landscape of stakeholder incentives and regulatory demands.
Main Methods:
- Literature review of historical trends in companion diagnostics.
- Analysis of market growth drivers, including economic incentives for drug developers.
- Examination of challenges related to stakeholder alignment (pharmaceutical companies, payers, providers) and regulatory requirements.
Main Results:
- Companion diagnostics have experienced substantial growth, expanding beyond oncology into new therapeutic areas.
- The number of CDx-drug combinations has increased significantly, with continued growth projected.
- Key challenges include aligning incentives among pharmaceutical companies, payers, providers, and regulators.
Conclusions:
- Companion diagnostics are integral to personalized medicine, with a strong growth trajectory.
- Diagnostic companies must adapt by broadening their strategies beyond single drug-diagnostic pairings and pursue consolidation and global expansion.
- Despite challenges, the companion diagnostics market presents significant opportunities and is a dynamic area for investment and innovation.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
Related Concept Videos
Automated Microbial Diagnostics
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
Therapeutic Drug Monitoring: Drug Analysis Methods